Overview
Canada health software provider's Q4 revenue rose 52% yr/yr, beating analyst expectations
Q4 adjusted EBITDA increased 47% yr/yr, margin improved sequentially with acquisition integration
Annual recurring revenue grew 35% yr/yr, driven by organic growth and acquisitions
Outlook
Company expects further improvement in adjusted EBITDA margin in 2026 from acquisition integration
Result Drivers
ACQUISITIONS - Co said acquisitions contributed to ARR and revenue growth, with integration supporting margin improvement
ORGANIC GROWTH - Organic expansion contributed to ARR and revenue increases
Company press release: ID:nGNX3SNdVl
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
C$31.4 mln
C$30.88 mln (10 Analysts)
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Vitalhub Corp is C$15.00, about 94.6% above its March 18 closing price of C$7.71
The stock recently traded at 32 times the next 12-month earnings vs. a P/E of 42 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
